JP5399612B2 - Ｃｎｓを治療するための融合タンパク質 - Google Patents

Ｃｎｓを治療するための融合タンパク質 Download PDF

Info

Publication number
JP5399612B2
JP5399612B2 JP2006533212A JP2006533212A JP5399612B2 JP 5399612 B2 JP5399612 B2 JP 5399612B2 JP 2006533212 A JP2006533212 A JP 2006533212A JP 2006533212 A JP2006533212 A JP 2006533212A JP 5399612 B2 JP5399612 B2 JP 5399612B2
Authority
JP
Japan
Prior art keywords
seq
chondroitinase
protein
tat
abci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006533212A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007516229A5 (enExample
JP2007516229A (ja
Inventor
グルスキン、エリオット、エー．
カッジアーノ、アンソニー、オー．
イアシ、ジェニファー
ジンバー、マイケル、ピー．
ロイ、ガージ
Original Assignee
アコーダ セラピューティクス、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アコーダ セラピューティクス、インク． filed Critical アコーダ セラピューティクス、インク．
Publication of JP2007516229A publication Critical patent/JP2007516229A/ja
Publication of JP2007516229A5 publication Critical patent/JP2007516229A5/ja
Application granted granted Critical
Publication of JP5399612B2 publication Critical patent/JP5399612B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2006533212A 2003-05-16 2004-05-17 Ｃｎｓを治療するための融合タンパク質 Expired - Fee Related JP5399612B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US47123903P 2003-05-16 2003-05-16
US47123603P 2003-05-16 2003-05-16
US47130003P 2003-05-16 2003-05-16
US60/471,239 2003-05-16
US60/471,236 2003-05-16
US60/471,300 2003-05-16
US47437203P 2003-05-29 2003-05-29
US60/474,372 2003-05-29
PCT/US2004/015661 WO2004110359A2 (en) 2003-05-16 2004-05-17 Fusion proteins for the treatment of cns

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012215041A Division JP5656314B2 (ja) 2003-05-16 2012-09-27 Ｃｎｓを治療するための融合タンパク質

Publications (3)

Publication Number Publication Date
JP2007516229A JP2007516229A (ja) 2007-06-21
JP2007516229A5 JP2007516229A5 (enExample) 2007-08-02
JP5399612B2 true JP5399612B2 (ja) 2014-01-29

Family

ID=33556640

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2006533212A Expired - Fee Related JP5399612B2 (ja) 2003-05-16 2004-05-17 Ｃｎｓを治療するための融合タンパク質
JP2012215041A Expired - Fee Related JP5656314B2 (ja) 2003-05-16 2012-09-27 Ｃｎｓを治療するための融合タンパク質
JP2014138911A Expired - Fee Related JP6141571B2 (ja) 2003-05-16 2014-07-04 Ｃｎｓを治療するための融合タンパク質
JP2017030467A Expired - Lifetime JP6913428B2 (ja) 2003-05-16 2017-02-21 Ｃｎｓを治療するための融合タンパク質
JP2020034479A Pending JP2020111578A (ja) 2003-05-16 2020-02-29 Ｃｎｓを治療するための融合タンパク質

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2012215041A Expired - Fee Related JP5656314B2 (ja) 2003-05-16 2012-09-27 Ｃｎｓを治療するための融合タンパク質
JP2014138911A Expired - Fee Related JP6141571B2 (ja) 2003-05-16 2014-07-04 Ｃｎｓを治療するための融合タンパク質
JP2017030467A Expired - Lifetime JP6913428B2 (ja) 2003-05-16 2017-02-21 Ｃｎｓを治療するための融合タンパク質
JP2020034479A Pending JP2020111578A (ja) 2003-05-16 2020-02-29 Ｃｎｓを治療するための融合タンパク質

Country Status (7)

Country Link
EP (3) EP3210999B1 (enExample)
JP (5) JP5399612B2 (enExample)
AU (1) AU2004247025B8 (enExample)
CA (1) CA2525782C (enExample)
ES (1) ES2831031T3 (enExample)
MX (2) MX351062B (enExample)
WO (1) WO2004110359A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666852B2 (en) * 2002-04-22 2010-02-23 Agenta Biotechnologies, Inc. Wound and cutaneous injury healing with a nucleic acid encoding a proteoglycan polypeptide
US8183350B2 (en) 2002-05-04 2012-05-22 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
EP3211084B1 (en) 2003-05-16 2019-03-27 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
MXPA06013345A (es) 2004-05-18 2008-10-31 Acorda Therapeutics Inc Metodos para purificar condrointinasa y sus formulaciones estables.
JP5189985B2 (ja) 2005-09-26 2013-04-24 アコーダ セラピューティクス、インク． コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
US8968728B2 (en) * 2006-05-12 2015-03-03 Bharat Biotech International Limited Chimeric fusion proteins
WO2007136042A1 (ja) 2006-05-19 2007-11-29 Aichi Prefecture 脳損傷改善剤
CA3009034C (en) 2006-10-10 2020-08-18 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
ES2437110T3 (es) * 2006-11-14 2014-01-08 Genentech, Inc. Moduladores de la regeneración neuronal
WO2008149428A1 (ja) * 2007-06-05 2008-12-11 Glycoscience Laboratories, Inc. 自己免疫疾患、炎症及び神経疾患の治療剤及び予防剤
AU2015200220A1 (en) * 2008-02-29 2015-02-12 Acorda Therapeutics, Inc. Method for achieving desired glial growth factor 2 plasma levels
WO2009108390A2 (en) * 2008-02-29 2009-09-03 Acorda Therapeutics, Inc. Method for achieving desired glial growth factor 2 plasma levels
EP2603221A4 (en) * 2010-08-13 2014-02-26 Univ Georgetown GGF2 AND METHOD FOR ITS APPLICATION
EP2756849B1 (en) * 2011-09-15 2016-03-16 Seikagaku Corporation Skeletal muscle regeneration promoter
GB201322396D0 (en) 2013-12-18 2014-02-05 Univ Nottingham Transduction
EP3475418A4 (en) * 2016-06-28 2020-03-04 Alma Mater Studiorum -Universita' di Bologna TATK-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS AND THEIR USE
US11396529B2 (en) 2020-11-12 2022-07-26 National Sun Yat-Sen University Isolated peptide, anti-cancer medicinal composition including the same and method of specifically reducing or inhibiting activities of cancer cells using the same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
AU697156B2 (en) * 1993-04-23 1998-10-01 American Cyanamid Company Cloning and expression of the chondroitinase I and II genes from (p. vulgaris)
AU1176595A (en) * 1993-11-12 1995-05-29 International Technology Management Associates, Ltd. Methods of repairing connective tissues
JPH07316068A (ja) * 1994-05-25 1995-12-05 Canji Inc 腫瘍サプレッサー融合タンパク質
GB9622500D0 (en) * 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
US20010006630A1 (en) * 1997-09-02 2001-07-05 Oron Yacoby-Zeevi Introducing a biological material into a patient
US6171575B1 (en) * 1998-04-06 2001-01-09 Shinichi Okuyama Method of radioisotopic assessment of the integrity and function of the nose-brain barrier
AU7497000A (en) * 1999-02-28 2000-11-14 Washington University Novel transduction molecules and methods for using same
CA2361292C (en) * 1999-03-16 2012-05-29 Edward A. Berger A novel chimeric protein for prevention and treatment of hiv infection
SE9901428D0 (sv) * 1999-04-21 1999-04-21 Karolinska Innovations Ab Amphibodies
CN101433715B (zh) * 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
CA2393186A1 (en) * 1999-12-02 2001-06-07 Ibex Technologies, Inc. Attenuation of fibroblast proliferation
US20020142299A1 (en) * 2001-01-09 2002-10-03 Davidson Beverly L. PTD-modified proteins
CA2367636C (en) * 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins
BR0211888A (pt) * 2001-08-13 2004-08-24 Univ Florida Res Foudantion In Materiais e métodos para promoção de reparo de tecido nervoso
GB0205022D0 (en) * 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
WO2003100031A2 (en) * 2002-05-20 2003-12-04 Board Of Regents, The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
AU2003265561A1 (en) * 2002-08-15 2004-03-03 Acorda Therapeutics, Inc. Chimeric protein

Also Published As

Publication number Publication date
CA2525782A1 (en) 2004-12-23
JP2013049677A (ja) 2013-03-14
JP5656314B2 (ja) 2015-01-21
ES2831031T3 (es) 2021-06-07
WO2004110359A9 (en) 2006-02-16
MXPA05012306A (es) 2006-04-18
AU2004247025B2 (en) 2011-06-23
EP2354155A2 (en) 2011-08-10
EP1646353A2 (en) 2006-04-19
JP2020111578A (ja) 2020-07-27
MX351062B (es) 2017-09-29
JP2017125035A (ja) 2017-07-20
JP6141571B2 (ja) 2017-07-12
EP3210999B1 (en) 2020-08-26
WO2004110359A2 (en) 2004-12-23
AU2004247025B8 (en) 2011-06-30
JP6913428B2 (ja) 2021-08-04
WO2004110359A3 (en) 2006-08-17
EP2354155A3 (en) 2011-09-07
JP2007516229A (ja) 2007-06-21
EP2354155B1 (en) 2017-05-03
CA2525782C (en) 2019-02-05
EP3210999A1 (en) 2017-08-30
AU2004247025A1 (en) 2004-12-23
JP2014221793A (ja) 2014-11-27
EP1646353A4 (en) 2008-06-04

Similar Documents

Publication Publication Date Title
JP6141571B2 (ja) Ｃｎｓを治療するための融合タンパク質
US8906363B2 (en) Fusion proteins for the treatment of CNS
JP2007516229A5 (enExample)
AU2014265113B2 (en) Fusion proteins for the treatment of cns
ES2638819T3 (es) Proteínas de fusión para el tratamiento del SNC

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110509

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120327

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120622

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120927

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130524

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130828

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130924

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131024

R150 Certificate of patent or registration of utility model

Ref document number: 5399612

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees